Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03407482 · ClinicalTrials.gov registry record · Phase 2
An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
A Phase 2 study, sponsored by Genentech.
- Terminated
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
NCT03407482 is a Phase 2 study that was terminated before completion, run by Genentech. The registered enrollment target is 160 participants.
The verdict
NCT03407482, a Phase 2 study, was terminated before completion, sponsored by Genentech.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
Study Summary
This Phase II, multicenter, open-label extension (OLE) study will evaluate the long-term safety and efficacy of GDC-0853 in participants with systemic lupus erythematosus (SLE) who have completed Study GA30044 (NCT02908100) up to 48 weeks.
Interventions
- DRUG GDC-0853
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2018-01-09 |
| Est. Completion | 2019-11-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03407482
The ClinicalTrials.gov registry entry for NCT03407482 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GDC-0853 is the first listed.
NCT03407482 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03407482 about?
NCT03407482 is a clinical study titled "An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus". This Phase II, multicenter, open-label extension (OLE) study will evaluate the long-term safety and efficacy of GDC-0853 in participants with systemic lupus erythematosus (SLE) who have completed Study GA30044 (NCT02908100) up to 48 weeks.
What is the current status of trial NCT03407482?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2018-01-09. Estimated completion is 2019-11-20.
What interventions are being tested in trial NCT03407482?
The interventions under investigation include: GDC-0853 (DRUG).
Who is sponsoring clinical trial NCT03407482?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.